[Early outcomes of controllable pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension: a single-centre experience at the Almazov National Medical Research Centre].
Controllable pulmonary thromboendarterectomy provides objective intraoperative assessment of completeness of PEA without prolonged circulatory arrest time and Hemodynamic, clinical and functional outcomes are consistent with the best international standards.
Abstract
Objective
To evaluate the early outcomes of original controllable pulmonary thromboendarterectomy (PEA) in the treatment of CTEPH.
MATERIAL AND
Methods
A single-center cohort retrospective-prospective study enrolled 74 CTEPH patients who underwent PEA between 2018 and 2024. All procedures were performed under deep hypothermic circulatory arrest using a patented method for assessing the completeness of endarterectomy (RF patent RU 2794557 C1). Original technique compares preoperative anatomical "map" of lesion (template No. 1) based on CT angiography and selective pulmonary angiography with intraoperative thromboembolic material placed on a sterile template No. 2. The primary endpoint was >50% reduction in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). Invasive assessment was performed immediately after surgery and at discharge.
Results
Median age was 52.5 years [43; 65]; 59.2% were male. A total of 73 patients (98.6%) completed the study. Cardiopulmonary bypass time was 216 min [188; 236], circulatory arrest time - 50 min [40; 60]. mPAP decreased by 62% [53.7; 68.2] at discharge from ICU; PVR dropped from 11.45 Wood units [7.4; 14.2] to 1.95 Wood units [1.4; 2.4] (p<0.001). Residual pulmonary hypertension (mPAP ≥25 mmHg and PVR ≥2.5 Wood units) was observed in 9 (12.3%) patients. The six-minute walk distance increased from 347 to 420 m (p<0.001); 85.7% of patients achieved NYHA class I-II. Complications included reperfusion pulmonary edema (41%), reintubation (8.1%), stroke (4.1%), and pneumonia (22.2%). In-hospital mortality was 1.4% (n=1; cause: generalized infection with multiple organ failure).
Conclusion
Controllable pulmonary thromboendarterectomy provides objective intraoperative assessment of completeness of PEA without prolonged circulatory arrest time. Hemodynamic, clinical and functional outcomes are consistent with the best international standards. The incidence of residual pulmonary hypertension and mortality do not exceed those of expert centers.
Background:
Chronic thromboembolic pulmonary hypertension (CTEPH) is the only form of pulmonary hypertension that is potentially curable by pulmonary endarterectomy (PEA). We report the outcomes of 60 consecutive PEA procedures performed by a single surgeon in a centre with a relatively low annual case volume.
Mate...
ABSTRACT Cold agglutinins can be detected in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during pulmonary thromboendarterectomy (PTE) pre‐operative testing. Peri‐operative management of these patients in anticipation of deep hypothermic circulatory arrest can be challenging and has not been stan...
Beenish Naqvi, M. Bautista, Amber P. Sanchez et al.· Pulmonary Circulation· 0 citations
PURPOSE
Percutaneous mechanical thrombectomy (PMT) is a promising treatment for pulmonary embolism (PE), especially in older patients at high bleeding risk. This study assessed its safety and efficacy in patients with acute PE aged over 75 years.
METHODS
Using data from the prospective, multicenter China Pulmonary Th...
Xiao-Jiang Wang, Ying-Jie Chen, Wei Yu et al.· Diagnostic and Interventiona...· 0 citations
Balloon pulmonary angioplasty (BPA) has emerged as a less invasive therapeutic option for chronic thromboembolic pulmonary hypertension (CTEPH). However, its clinical efficacy and procedural safety still need comprehensive evaluation. This study aims to investigate the effects of BPA in patients with inoperable C...
M. Salvi, D. Guarino, A. Ballerini et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.